Carbohydrate anti-tumor drugs are a new type of anti-tumor preparation developed based on carbohydrate compounds, which exert their effects by targeting tumor cell metabolism or regulating the immune system. These drugs typically have natural polysaccharides, oligosaccharides, or synthetic sugar conjugates as their core structures, which can interfere with the energy metabolism of tumor cells, inhibit glycosylation processes, or block glycoprotein mediated cell signaling, thereby inhibiting tumor proliferation and metastasis. Compared to traditional chemotherapy drugs, carbohydrate anti-tumor drugs have higher targeting and lower toxic side effects. For example, heparin derivatives can inhibit tumor angiogenesis, and chitosan complexes can enhance immune cell activity.Anti-tumor glycodrugs leverage their unique sugar chain structures to precisely target tumor cells, enhancing biocompatibility and therapeutic efficacy. The sugar chains bind to specific receptors on tumor cell surfaces, inhibiting proliferation, migration, and angiogenesis while inducing apoptosis. Additionally, glycodrugs modulate the immune microenvironment, activating immune cells (e.g., LAK, NK cells) and boosting the body's anti-tumor immune response. Their low toxicity and high targeting specificity make them promising candidates for cancer treatment.The wide variety of medications has greatly met people's needs.
